Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $106.4 million.

  • Akebia Therapeutics' Accumulated Expenses rose 10381.12% to $106.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.4 million, marking a year-over-year increase of 10381.12%. This contributed to the annual value of $63.5 million for FY2024, which is 631.14% down from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Accumulated Expenses is $106.4 million, which was up 10381.12% from $91.6 million recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Accumulated Expenses peaked at $144.7 million during Q3 2021, and registered a low of $51.1 million during Q1 2023.
  • Moreover, its 5-year median value for Accumulated Expenses was $75.8 million (2022), whereas its average is $84.1 million.
  • Per our database at Business Quant, Akebia Therapeutics' Accumulated Expenses plummeted by 5528.92% in 2023 and then soared by 10381.12% in 2025.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Accumulated Expenses stood at $109.0 million in 2021, then tumbled by 30.49% to $75.8 million in 2022, then fell by 10.61% to $67.7 million in 2023, then dropped by 6.31% to $63.5 million in 2024, then surged by 67.7% to $106.4 million in 2025.
  • Its Accumulated Expenses stands at $106.4 million for Q3 2025, versus $91.6 million for Q2 2025 and $71.3 million for Q1 2025.